Context Therapeutics Inc. (CNTX)
NASDAQ: CNTX · Real-Time Price · USD
0.3643
-0.0254 (-6.52%)
At close: Sep 1, 2026, 4:00 PM EDT
0.3754
+0.0111 (3.05%)
After-hours: Sep 1, 2026, 7:57 PM EDT
Context Therapeutics Employees
Context Therapeutics had 15 employees as of December 31, 2025. The number of employees increased by 3 or 25.00% compared to the previous year.
Employees
15
Change (1Y)
3
Growth (1Y)
25.00%
Revenue / Employee
n/a
Profits / Employee
-$3,063,856
Market Cap
33.47M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 15 | 3 | 25.00% |
| Dec 31, 2024 | 12 | 7 | 140.00% |
| Dec 31, 2023 | 5 | -4 | -44.44% |
| Dec 31, 2022 | 9 | - | - |
| Jun 30, 2021 | 2 | - | - |
| Mar 31, 2021 | 2 | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| IGC Pharma | 70 |
| Mereo BioPharma Group | 39 |
| Quince Therapeutics | 38 |
| Kyntra Bio | 34 |
| Actinium Pharmaceuticals | 27 |
| BriaCell Therapeutics | 16 |
| CervoMed | 15 |
| TransCode Therapeutics | 12 |
CNTX News
- 26 days ago - Context downgraded to Market Perform from Outperform at LifeSci Capital - TheFly
- 26 days ago - Context Therapeutics price target lowered to $3 from $4 at Citizens - TheFly
- 27 days ago - Context Therapeutics reports Q2 EPS (15c), consensus (9c) - TheFly
- 27 days ago - Context Therapeutics Reports Second Quarter 2026 Operating and Pipeline Progress - GlobeNewsWire
- 27 days ago - Context Therapeutics Quarterly report: Q2 2026 - Filings
- 27 days ago - Context Therapeutics Earnings release: Q2 2026 - Filings
- 4 weeks ago - Context Therapeutics Slides: Corporate presentation - Filings
- 7 weeks ago - Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire